Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers

PurposePhotodynamic therapy (PDT) is a new approach to cancer treatment that utilizes photochemical reactions induced by a combination of an oncophilic photosensitizing agent and laser light. With an aim to apply PDT for intraperitoneal disseminated foci of advanced or recurrent ovarian cancers, the present study was conducted to evaluate the antitumor effect of PDT using a methyl ester of 5-aminolevulinic acid (Methyl-ALA) on various types of human ovarian cancer in a subcutaneous xenograft model in nude mice and to elucidate the mechanism of its antitumor effect.MethodsHTOA, MCAS, and TOV21G cell lines derived from human ovarian serous, mucinous, and clear cell adenocarcinoma, respectively, were used in this study. The mice in the treatment group and in the control group received an intraperitoneal injection of 250 mg/kg of Methyl-ALA and PBS alone, respectively. PDT was administered by 10 min irradiation using a 150 W halogen light, 3 h after Methyl-ALA or PBS injection. Each mouse received PDT twice a week for 3 weeks.ResultsMethyl-ALA-PDT significantly suppressed the growth of HTOA tumors as compared to control, whereas there was no significant effect on the growth of MCAS or TOV21G tumors. Methyl-ALA-PDT significantly increased apoptosis in implanted HTOA tumors as well as cultured cells. Western blot analysis showed that amount of expression of milk fat globule-EGF-factor 8, which binds to apoptotic cells and thereby facilitates their phagocytosis, significantly increased in HTOA tumors receiving Methyl-ALA-PDT, compared with untreated HTOA tumors. In addition, reduced vascular endothelial growth factor and CD34-positive microvessel density were found in solid HTOA tumors treated by Methyl-ALA-PDT, suggesting that the antitumor effect of Methyl-ALA-PDT is due to induction of apoptosis and reduction of angiogenesis. In comparison with HTOA cells, HPLC analysis demonstrated a significantly smaller intracellular amount of protoporphyrin IX (PpIX) in MCAS and TOV21G cells. PpIX is readily converted from Methyl-ALA and elicts photocytotoxicity.ConclusionWe conclude that Methyl-ALA-PDT could be an effective treatment in ovarian cancer and should be tested to apply intraperitoneally disseminated micro-foci during surgery.

[1]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[2]  F. Obermair,et al.  Differential effects of glucose deprivation on the cellular sensitivity towards photodynamic treatment‐based production of reactive oxygen species and apoptosis‐induction , 2005, FEBS letters.

[3]  Y. Saito,et al.  Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. , 1999, European journal of gynaecological oncology.

[4]  H. Mizunuma,et al.  Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor γ in epithelial ovarian tumours , 2004, British Journal of Cancer.

[5]  T. Hasan,et al.  Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy. , 2008, Cancer letters.

[6]  Alan D. Lopez,et al.  Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000 , 2002, BMC Cancer.

[7]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .

[8]  Patrizia Agostinis,et al.  Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. , 2007, Biochimica et biophysica acta.

[9]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[10]  P. Lou,et al.  Effect of 5‐aminolevulinic acid‐mediated photodynamic therapy on MCF‐7 and MCF‐7/ADR cells , 2004, Lasers in surgery and medicine.

[11]  Mitsuaki Suzuki,et al.  Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. , 2009, Gynecologic oncology.

[12]  R. Ho,et al.  Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. , 2008, Toxicology letters.

[13]  P. Calzavara-Pinton,et al.  Photodynamic therapy: update 2006 Part 1: Photochemistry and photobiology , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  J. Kigawa,et al.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging , 2006, British Journal of Cancer.

[15]  Malini Olivo,et al.  A study comparing endogenous protoporphyrin IX induced by 5-ALA and ALA-methyl ester with exogenous PpIX and PpIX dimethyl ester in photodynamic diagnosis of human nasopharyngeal carcinoma xenografts. , 2006, International journal of oncology.

[16]  J Moan,et al.  Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. , 2001, Cancer research.

[17]  S. Tsuchida,et al.  Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer , 2001, British Journal of Cancer.

[18]  J. Piette,et al.  Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy , 2004, Oncogene.

[19]  P. Kaiser.  Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration , 2007, Current medical research and opinion.

[20]  T. Dougherty.  Photodynamic therapy. , 1993, Photochemistry and photobiology.

[21]  Keiko Miwa,et al.  Identification of a factor that links apoptotic cells to phagocytes , 2002, Nature.